Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Proceedings of the National Academy of Sciences · 17.01.2023 · 120 (3)
DOI: 10.1073/pnas.2207291120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 12.01.2023. Verfasst von Koji Shinoda und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Multiple Sclerosis. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting deeper depletion of CD20-expressing cells with repeat infusions. We assessed cellular immune profiles and their association with transient disease activity following anti-CD20 initiation as a window into relapsing disease biology. Peripheral blood mononuclear cells from independent discovery and validation cohorts of MS patients initiating ocrelizumab were assessed for phenotypic and functional profiles using multiparametric flow cytometry. Pretreatment CD20-expressing T cells, especially CD20 dim CD8 + T cells with a highly inflammatory and central nervous system (CNS)-homing phenotype, were significantly inversely correlated with pretreatment MRI gadolinium-lesion counts, and also predictive of early disease activity observed after anti-CD20 initiation. Direct removal of pretreatment proinflammatory CD20 dim CD8 + T cells had a greater contribution to treatment-associated changes in the CD8 + T cell pool than was the case for CD4 + T cells. Early disease activity following anti-CD20 initiation was not associated with reconstituting CD20 dim CD8 + T cells, which were less proinflammatory compared with pretreatment. Similarly, this disease activity did not correlate with early reconstituting B cells, which were predominantly transitional CD19 + CD24 high CD38 high with a more anti-inflammatory profile. We provide insights into the mode-of-action of anti-CD20 and highlight a potential role for CD20 dim CD8 + T cells in MS relapse biology; their strong inverse correlation with both pretreatment and early posttreatment disease activity suggests that CD20-expressing CD8 + T cells leaving the circulation (possibly to the CNS) play a particularly early role in the immune cascades involved in relapse development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Center for Neuroinflammation and Experimental Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado School of Medicine, Aurora, CO 80045.
- F. Hoffmann-La Roche, 4070 Basel, Switzerland.
- Department of Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada.
- Multiple Sclerosis Center of Northeastern New York, Comprehensive MS Care Center Affiliated with the National MS Society, Latham, NY 12110.
ORCID-Profile: Koji Shinoda, Rui Li, Mihir Kakara, H-Christian von Büdingen, Paul S Giacomini, Benjamin M Greenberg, David A Hafler, Christopher B Lock, Gabriel Pardo, Fredrik Piehl, Martin S Weber, Tjalf Ziemssen, Anne H Cross, Briana Cameron, Ryan C Winger
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
Zitieren
APA
Shinoda, K., Li, R., Rezk, A., Mexhitaj, I., Patterson, K. R., Kakara, M., Zuroff, L., Bennett, J. L., von Büdingen, H. C., Carruthers, R., Edwards, K. R., Fallis, R., Giacomini, P. S., Greenberg, B. M., Hafler, D. A., Ionete, C., Kaunzner, U. W., Lock, C. B., Longbrake, E. E., …, & Bar-Or, A. (2023). Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings of the National Academy of Sciences, 120(3). https://doi.org/10.1073/pnas.2207291120
Vancouver
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson KR, Kakara M, et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings of the National Academy of Sciences. 2023;120(3). doi:10.1073/pnas.2207291120
BibTeX
@article{Shinoda2023,
author = {Shinoda, Koji and Li, Rui and Rezk, Ayman and Mexhitaj, Ina and Patterson, Kristina R and Kakara, Mihir and Zuroff, Leah and Bennett, Jeffrey L and von Büdingen, H-Christian and Carruthers, Robert and Edwards, Keith R and Fallis, Robert and Giacomini, Paul S and Greenberg, Benjamin M and Hafler, David A and Ionete, Carolina and Kaunzner, Ulrike W and Lock, Christopher B and Longbrake, Erin E and Pardo, Gabriel and Piehl, Fredrik and Weber, Martin S and Ziemssen, Tjalf and Jacobs, Dina and Gelfand, Jeffrey M and Cross, Anne H and Cameron, Briana and Musch, Bruno and Winger, Ryan C and Jia, Xiaoming and Harp, Christopher T and Herman, Ann and Bar-Or, Amit},
title = {Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {3},
doi = {10.1073/pnas.2207291120}
}
EUVIMED